What Cytokinetics, Incorporated's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 16 | 85 |
| Total trades | 37 | 212 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 178,057 | 932,420 |
| Disposed | 283,202 | 892,711 |
| Net activity | −105,145 | +39,709 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Malik Fady Ibraham | EVP Research & Development | Oct 20 | Open-market sale · S | −3,500 | $64.01 | −$224K | 153,902 |
| Malik Fady Ibraham | EVP Research & Development | Oct 20 | Exercise / conversion · M | +3,500 | $7.80 | +$27.3K | 157,402 |
| Wysenski Nancy | Director | Oct 16 | Grant / award · A | +97 | $63.92 | +$6.2K | 34,089 |
| Kaye Edward M. Md | Director | Oct 16 | Grant / award · A | +195 | $63.92 | +$12.5K | 10,629 |
| Harrington Robert Arthur | Director | Oct 16 | Grant / award · A | +195 | $63.92 | +$12.5K | 22,127 |
| Daly James M | Director | Oct 16 | Grant / award · A | +195 | $63.92 | +$12.5K | 3,585 |
| Wierenga Wendell | Director | Oct 16 | Grant / award · A | +97 | $63.92 | +$6.2K | 35,660 |
| Henderson John T | Director | Oct 16 | Grant / award · A | +352 | $63.92 | +$22.5K | 78,712 |
| Blum Robert I | President & CEO | Oct 12 | Open-market sale · S | −7,500 | $62.88 | −$472K | 278,544 |
| Blum Robert I | President & CEO | Oct 12 | Exercise / conversion · M | +7,500 | $10.60 | +$79.5K | 286,044 |
| Malik Fady Ibraham | EVP Research & Development | Oct 06 | Open-market sale · S | −3,500 | $61.38 | −$215K | 153,902 |
| Malik Fady Ibraham | EVP Research & Development | Oct 06 | Exercise / conversion · M | +3,500 | $7.80 | +$27.3K | 157,402 |
| Blum Robert I | President & CEO | Sep 28 | Open-market sale · S | −7,500 | $65.46 | −$491K | 278,544 |
| Blum Robert I | President & CEO | Sep 28 | Exercise / conversion · M | +7,500 | $10.60 | +$79.5K | 286,044 |
| Malik Fady Ibraham | EVP Research & Development | Sep 22 | Open-market sale · S | −3,500 | $68.29 | −$239K | 153,902 |
| Malik Fady Ibraham | EVP Research & Development | Sep 22 | Exercise / conversion · M | +3,500 | $7.80 | +$27.3K | 157,402 |
| Blum Robert I | President & CEO | Sep 15 | Open-market sale · S | −97,926 | $69.33 | −$6.79M | 0 |
| Landry Robert E | Director | Sep 15 | Open-market sale · S | −1,000 | $72.13 | −$72.1K | 8,184 |
| Blum Robert I | President & CEO | Sep 14 | Gift · G | +97,926 | — | — | 97,926 |
| Blum Robert I | President & CEO | Sep 14 | Gift · G | −97,926 | — | — | 278,544 |
Loading...
